Abstract: Alkylglycerol monooxygenase (AGMO; EC 1.14.16.5) is the only enzyme known to cleave the O-alkyl ether bond of alkylglycerols in humans. It is an integral membrane protein with nine predicted transmembrane domains. We attempted to express and purify full-length and truncated forms of AGMO in Escherichia coli . Full-length AGMO could not be expressed in three different E. coli expression strains, three different expression vectors and several induction systems. We succeeded, however, in expression of three N-terminally strep-tagged truncated forms, named active sites 1, 2 and 3, with 205, 134 and 61 amino acids, respectively. Active site 1 fragment, containing two predicted transmembrane regions, a membrane associated region and all known amino acid residues important for catalytic activity, was not fully soluble even in 8 M urea. Active site 2 containing only one predicted membrane associated domain required 8 M urea for solubilisation and eluted in gel filtration in 1 M urea as a trimer. Active site 3 with no hydrophobic domain eluted in gel filtration in 1 M urea as monomer and dimer. These results show that even truncated forms of AGMO are barely soluble when expressed in E. coli and show a high tendency for aggregation.
Introduction
Ether lipids are abundant in higher eukaryotic membranes [ 1 ] . They have been shown to play an important role in the inhibition of cataract formation and signalling processes. Furthermore, they are a major component of brain membranes and are also involved in spermatogenesis [ 1 ] . Alkylglycerol monooxygenase (AGMO) is found in the endoplasmic reticulum of cells and shows highest activity in rat liver. It is the only enzyme known to cleave the O-alkyl ether bond of alkylglycerols in a tetrahydrobiopterin-dependent reaction yielding a free aldehyde and a glycerol derivative [ 2 ] . Fatty aldehyde hydroxylase (FALDH; EC 1.2.1.48) detoxifies the reactive free aldehyde through a NAD-dependent conversion to the corresponding fatty acid [ 3 ] . Although its function was first described in 1964, the AGMO sequence remained unknown until 2010 because it was impossible to purify this labile integral membrane enzyme without loss of activity. Only by selecting candidate genes by bioinformatic approaches and by proteomic analysis of partially purified fractions containing AGMO enzymatic activity and transiently transfecting 10 of them into mammalian cells, it could be shown that transmembrane protein 195 (TMEM195), an open reading frame with unknown function, was able to confer AGMO activity to cells [ 4 ] . Human AGMO shows no sequence homology to the two other classes of tetrahydrobiopterin-dependent enzymes (aromatic amino acid hydroxylases and nitric oxide synthases), and therefore it forms a third class of tetrahydrobiopterin-dependent enzymes [ 4 ] . AGMO contains a fatty acid hydroxylase motif and nine predicted transmembrane regions [ 4 , 5 ] . It is not known whether the enzyme is active as a monomer or an oligomer. A secondary structure prediction and an ab initio calculation of the catalytic centre of the reaction [ 5 ] facilitated the design of three different N-terminally strep-tagged fragments with decreasing hydrophobicity ( Figure 1 ). Here, we report our attempts to express full-length and truncated N-terminally strep-tagged peptides of AGMO in Escherichia coli , solubilise and purify them with Strep-Tactin affinity chromatography and gel filtration. TM1 TM2 TM3  TM4 TM5  TM6 TM7 TM8 TM9  MAD   205 
Materials and methods

Materials
Most chemicals were purchased from Sigma-Aldrich (Schnelldorf, Germany), Roth (Karlsruhe, Germany), Merck (Darmstadt, Germany), Serva (Heidelberg, Germany) and Lactan (Graz, Austria). Chemicals purchased by other companies are mentioned in the text. 
Methods Cloning
Expression
Full-length human AGMO in pPR-IBA2 was tested in all three E. coli strains. Full-length human AGMO in vectors pET28b, pPR-IBA2 and pPR-IBA101 was tested in Lemo21(DE3) . The diff erent strains were induced with isopropyl-β -D-1-thiogalactopyranoside (IPTG) according to the manufacturer ' s instructions. Expression was tested up to 24 h. Cultures were shaken at 225 rpm and 37 ° C. In some experiments, 15 ° C was used instead to induce chaperone expression in E. coli [ 7 ] . An autoinduction protocol was tested for full-length human AGMO expression in all three strains transformed with human alkylglycerol monooxygenase-pPR-IBA2 [ 8 ] at 37 ° C. Expression of active site 1 was tested in all three expression strains [6 h of expression at 37 ° C, 225 rpm in 100 mL Terrifi c Broth (TB) medium]. Then, 1 mL samples (0 h, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 24 h aft er induction) were collected by centrifugation, the pellets digested with lysozyme [100 mM phosphate buff er pH 7.0, 1 mM ethylenediamine-tetraacetic acid (EDTA), 1 mM dithiothreitol (DTT), 1 mM phenylmethanesulfonylfl uoride (PMSF), 0.1 mg/mL lysozyme, 10 U/mL DNAseI] for 20 min at 25 ° C shaken with 650 rpm, homogenised with an ultra-turrax (T8, Ika GmbH, Staufen, Germany). Protein content was measured by Bradford assay using bovine serum albumin as standard [ 9 , 10 ] and tested by Western blot (10 μ g protein per lane) using anti-Strep-Tactin horse radish peroxidise (IBA GmbH). Larger cell pellets were homogenised using a French press (SLM Alminco, SLM Instruments, Corston, UK) aft er the lysozyme digest procedure.
Protein purification
(1) Membrane preparation . Membranes were prepared with two consecutive centrifugation steps at 4 ° C [3000 × g (Megafuge 2.0 RS, Heraeus, Kendro Laboratory Products, Osterode, Germany) and 55,000 × g (Beckman Coulter Avanti J-26XP, Beckman, Fullerton, CA, USA) at 4 ° C for 30 min and 60 min, respectively]. The insoluble fractions aft er the 55,000 × g centrifugation step were washed twice with 0.5% (w/v) deoxycholate and then centrifuged at 55,000 × g again. The insoluble fraction was resolubilised with the chaotropic agent urea (6 or 8 M) at a pH of 9.0 for 1 h at 25 ° C shaking at 225 rpm. Solubility was tested by an additional centrifugation step at 100,000 × g (Beckman Optima TLX Ultracentrifuge, Beckman) for 15 min at 4 ° C.
(2) Strep-Tactin affi nity chromatography . For Strep-Tactin affi nity chromatography, the resolubilised insoluble fraction (see above) was diluted 1:16 or 1:20 to reduce the urea concentration under 1 M by addition of 100 mM Tris HCl, pH 9.0, containing 150 mM NaCl, and 1 mM EDTA according to the compatibility between reagents and resin and centrifuged again at 17,000 × g for 15 min at 4 ° C. Affi nity chromatography was performed with Strep-Tactin Superfl ow (Iba, Goettingen, Germany). Aft er application of the protein the column was washed with four to fi ve column volumes of 100 mM Tris HCl, pH 9.0, containing 150 mM NaCl, and 1 mM EDTA and the protein was eluted with 2.5 mM desthiobiotin (100 mM Tris HCl, 150 mM NaCl, 1 mM EDTA, pH 9.0). The OD 280 peak fractions (Pharmacia Uvicord SII, GE Healthcare) were collected and the pH was shift ed to 12 with sterile fi ltered 3 N NaOH, and the urea concentration was increased to 1 M using 8 M urea solution, pH 12, containing 150 mM NaCl and 1 mM EDTA. Pooled elution peak fractions were concentrated by ultrafi ltration (Vivaspin 4 column, Vivascience) at 3000 × g and 4 ° C. (3) Gel-fi ltration . Gel-fi ltration with a Superose 12/10/300 column (GE Healthcare) was used as an analytical step to investigate aggregation and as a fi nal preparative step. Three conditions were tested for separation of both active site 2 and active site 3. Running buff er (100 mM Tris HCl, pH 12.0, 150 mM NaCl, 1 mM EDTA) was supplemented with either 1 M urea, 6 M urea or 0.1% (w/v) sodium dodecyl sulphate (SDS) at a fl ow of 0.5 mL/min. Eluting protein was detected by UV absorption at 280 nm (Ti Series 1050, Agilent Technologies, Vienna, Austria). Molecular mass markers used were thyreoglobulin (670 kDa), β -amylase (200 kDa), equine serum albumin (67 kDa), myoglobin (18 kDa) and FAD (0.8 kDa). Peak fractions were analysed by Coomassie stained SDS-PAGE, Western blot analyses (anti-StrepTactin horse radish peroxidase, IBA GmbH) and by mass spectrometry (MALDI-TOF-TOF, performed at the Division of Clinical Biochemistry, Innsbruck Medical University).
Results
Expression of full-length human AGMO
In all tested conditions which include three bacterial strains, three different expression vectors and different induction protocols (15 ° C and 37 ° C, induction by IPTG or lactose) full-length human AGMO could not be expressed as determined by anti-Strep-Tactin Western blotting. We therefore attempted to express shorter fragments of human AGMO in E. coli.
Expression of active sites 1, 2 and 3
Three truncated N-terminal strep-tagged ® fragments were cloned (for details see Methods section) and expression was tested in all three E. coli strains ( Figure 2 ). Highest expression of active site 1 was achieved in the KRX strain ( Figure 2 ), detectable levels of active site 1 were obtained in BL21-CodonPlus(DE3)-RIL ( Figure 2 ) . Lemo21(DE3) , a BL21(DE3) derivative, showed no expression of active site 1 ( Figure 2 ). When testing expression of active sites 2 and 3 in KRX cells, similar levels were obtained as for active site 1 and therefore further studies were performed with the KRX strain.
Solubilisation and purification of active sites 1, 2 and 3
Preparative expression of all three human AGMO fragments was performed in KRX cells. After membrane preparation, all three fragments were insoluble in detergentfree buffer and had to be washed with deoxycholate and resolubilised with urea (8 M urea for active sites 1 and 2, 6 M urea for active site 3; Figure 3 ). Active site 1 was not fully soluble even in 8 M urea. By contrast, active site 2 was fully soluble after membrane preparation at 8 M urea. Active site 3 could be fully solubilised in 6 M urea. Therefore, we were able to further purify active site 2 and active site 3 with Strep-Tactin affinity chromatography. As a final purification step, we then used gel filtration at pH 12.0 with 1 M urea as an eluent ( Figure 4 ) . To obtain a monomeric peak of active sites 2 and 3, we tried to increase the molarity of urea to 6 M, or to use the detergent SDS (0.1% w/v). Both conditions did not lead to monomerisation (not shown). Thus, even at pH 12 and 1 M urea active site 2 elutes as a trimer, and active site 3 as an approximately equal mixture of monomers and dimers ( Figure 3 ) . We checked gel-filtration peaks for purity by Coomassie stained SDS-PAGE gel ( Figure 5 ). After concentrating those fractions containing the highest amount of protein obtained during gel filtration by ultrafiltration, a 17-kDa band with immunoreactivity to the anti-Strep-Tactin antibody was identified for the active site 2 gel filtrate, corresponding to the calculated molecular mass (17 kDa) of this fragment ( Figure 4 A) . In the active site 3 gel filtrate, however, three different bands were found, at approximate molecular masses of the monomer (8.5 kDa), the dimer (17 kDa) and the trimer (25.5 kDa; Figure 5 The three fragments were expressed as N-terminally strep-tagged proteins in KRX cell membranes prepared and resolubilised with urea. Resolubilised samples (10 μ L) were separated on a 15% Tristricine (for active site 1 and active site 3) or 20% polyacrylamide (for active site 2) gel and stained with anti-Strep-Tactin horse radish peroxidase antibody conjugate. SUP, supernatant after resolubilisation and centrifugation at 100,000 × g ; PELLET, pellet after resolubilisation and centrifugation at 100,000 × g . The migration of molecular mass markers is shown by arrows. The urea concentration used is indicated at the bottom of the figure. Bands were excised and analysed by mass spectrometric analysis. All bands were identified as human AGMO fragments. This led us to the conclusion that even small fragments of human AGMO partly aggregated when incubated with SDS and β -mercaptoethanol in SDS-PAGE.
Discussion
This study shows for the first time expression and purification of a truncated form of human AGMO in amounts suitable for immunisation and other biochemical approaches. Whereas full-length human AGMO was resistant to expression in different bacterial hosts and from different vectors, a smaller fragment containing all or at least parts of the proposed catalytically active site [ 5 ] could be expressed in E. coli . It was, however, very surprising to see that even though these fragments were thoroughly chosen to harbour less and less hydrophobic segments, we were not able to fully solubilise the two longer fragments, and the smaller fragment still showed a very high tendency to aggregate. Human AGMO active site 1 (235 amino acids) is predicted to contain only two of the nine transmembrane segments found in full-length protein and also has one membrane associated domain and a hydrophilic loop. This protein could not be solubilised even in high urea concentrations. By contrast, human AGMO active site 2 (134 amino acids), which only has a single predicted membrane associated domain, and the hydrophilic loop could be solubilised in 8 M urea, but in gel filtration it appeared oligomerised. Oligomerisation was less in the shorter human AGMO active site 3 (61 amino acids, only the hydrophilic loop was present), but still it eluted as a dimer-monomer mixture in gel filtration. Not even the stringent conditions in SDS-PAGE sample preparation (5%, v/v, β -mercaptoethanol) and during the SDS-PAGE run (0.2%, w/v, SDS) were able to break these interactions fully. Although fairly rare, there are other proteins mentioned in the literature which are SDS resistant. Intermediate II [ 11 ] oligomers of α -synuclein (14 kDa) have been described to be resistant to 0.2% SDS and synaptogamin I [ 12 ] is insensitive to β -mercaptoethanol and 1% (w/v) SDS. Further attempts will be needed to optimise expression of longer AGMO fragments and also the full-length protein to allow future biochemical and structural studies. Changing the expression host from bacteria to a eukaryotic cell system might provide a more adequate setting for expression, folding and processing of such a highly hydrophobic enzyme.
